当前位置：易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型：会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
易推广会员：5年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
企业类型：生产商 【已认证】
注册资金：人民币万 【已认证】
产品数：86101
参观次数：3451546
自主品牌
已选条件
-
T6229Daclatasvir达卡他韦；达拉他韦；BMS-790052；EBP 883；Daklinza
Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
价 格：￥电议型 号：T6229产 地：中国大陆
-
T1786Daclatasvir dihydrochlorideBMS-790052 dihydrochloride；盐酸达拉他韦
Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir
价 格：￥电议型 号：T1786产 地：中国大陆
-
T1786Daclatasvir dihydrochlorideDaclatasvir dihydrochloride,BMS-790052 dihydrochloride,
Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir
价 格：￥电议型 号：T1786产 地：美洲
-
T6229DaclatasvirDaclatasvir,EBP 883,BMS-790052
Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
价 格：￥电议型 号：T6229产 地：美洲
-
T6229Daclatasvir达拉他韦Daklinza|||达卡他韦|||EBP 883|||达拉他韦|||BMS-790052
Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
价 格：￥电议型 号：T6229产 地：中国大陆
-
T1786Daclatasvir dihydrochloride；盐酸达拉他韦BMS-790052 dihydrochloride；BMS-790052 dihydrochloride|||盐酸达拉他韦
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice.
价 格：￥电议型 号：T1786产 地：中国大陆
